(Total Views: 543)
Posted On: 10/08/2025 7:38:18 AM
Post# of 157846
More on Hot and Cold Tumors:
Excerpt: “Our findings show that we can therapeutically induce functional TLS in otherwise immune‑cold tumors, ” says Masanobu Komatsu, Ph.D., principal investigator of the study and senior scientist at the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. “By building the right immune infrastructure inside tumors, we can potentiate the patient’s own defenses—both T cell and B cell arms —against cancer growth, relapse, and metastasis.”
Because TLS abundance correlates with better outcomes across many tumor types, the use of the two protein stimulators together may offer a broadly applicable way to enhance the effectiveness of existing therapies, including checkpoint inhibitors that are the mainstay of immunotherapies, and traditional chemotherapy."
We are in all the right neighborhoods of breaking science.
https://scitechdaily.com/scientists-superchar...ming-back/
Excerpt: “Our findings show that we can therapeutically induce functional TLS in otherwise immune‑cold tumors, ” says Masanobu Komatsu, Ph.D., principal investigator of the study and senior scientist at the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. “By building the right immune infrastructure inside tumors, we can potentiate the patient’s own defenses—both T cell and B cell arms —against cancer growth, relapse, and metastasis.”
Because TLS abundance correlates with better outcomes across many tumor types, the use of the two protein stimulators together may offer a broadly applicable way to enhance the effectiveness of existing therapies, including checkpoint inhibitors that are the mainstay of immunotherapies, and traditional chemotherapy."
We are in all the right neighborhoods of breaking science.
https://scitechdaily.com/scientists-superchar...ming-back/
(6)
(0)
